Nalmefene

Chemical formula: C₂₁H₂₅NO₃ Molecular mass: 339.435 g/mol

Therapeutic indications

Nalmefene is indicated for:

Reduction of alcohol consumption

Population group: only adults (18 years old or older)

Nalmefene is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification.

Nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.

Nalmefene should be initiated only in patients who continue to have a high DRL two weeks after initial assessment.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

18.06 mg once

Contraindications

Nalmefene is contraindicated in the following cases:

Opioid agonists

Opioids

Opioid addiction

Opioid dependence

Opioid withdrawal

Severe hepatic impairment (Child-Pugh classification)

Hepatic failure stage IV

Severe renal impairment (eGFR <30 ml/min per 1.73 m²)

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Acute alcohol withdrawal syndrome

Alcohol withdrawal syndrome

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.